Susquehanna Defends Dick's (DKS) Amid Today's 7% Decline
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/12/2026
- Oil rally pressures S&P, Nasdaq; Microsoft, Salesforce buoy Dow
- Oil prices rise 2% as attacks on Saudi Arabia overshadow Trump's diesel deal
- Will surging equity supply derail the U.S. bull market? Goldman Sachs weighs in
- Broadcom CEO says many AI investors are gamblers
- "Not buying Chipotle": Starbucks squashes blockbuster acquisition speculation
Tweet
Share
E-mailGet Alerts DKS Hot Sheet
Price: $136.31 -0.25%
Rating Summary:
25 Buy, 25 Hold, 2 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 19 | Down: 20 | New: 46
Rating Summary:
25 Buy, 25 Hold, 2 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 19 | Down: 20 | New: 46
Join SI Premium – FREE
An analyst at Susquehanna Friday afternoon issued a note arguing the nearly 7 percent sell-off in shares of Dick's (NYSE: DKS) is overdone.
The stock plunged at the open earlier following a warning from an analyst at Cleveland Research who believes the company's latest quarter is tracking to the low-end or possibly below its guidance range.
Susquehanna sees general promotional pressure as seasonal and actually lower based on a year-over-year comparisons.
The firm maintains its Positive rating and $47 price target.
With Dick's shares last trading at $37.88, Susquehanna's price target implies potential upside of about 24 percent.
The stock plunged at the open earlier following a warning from an analyst at Cleveland Research who believes the company's latest quarter is tracking to the low-end or possibly below its guidance range.
Susquehanna sees general promotional pressure as seasonal and actually lower based on a year-over-year comparisons.
The firm maintains its Positive rating and $47 price target.
With Dick's shares last trading at $37.88, Susquehanna's price target implies potential upside of about 24 percent.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Biogen (BIIB) PT Raised to $220 at BMO Capital
- Jefferies: 'we estimate that Starlink is on 9% of aircraft today and will be on 23% by 2028'
- Raymond James on Mirum Pharmaceuticals (MIRM): 'we think its ~$1B+ estimate for the Livmarli opportunity is continuing to look more and more conservative'
Create E-mail Alert Related Categories
Analyst CommentsRelated Entities
Susquehanna International Group of CompaniesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
